Total raised
—
Stage
Pre-Funding
Founded
2019
Headcount
6
HQ
Be'er Sheva
Sector
Health Tech & Life Sciences
About
Molbrick is a start-up developing novel antimicrobial agents to treat drug-resistant mycobacteria. It has designed small-molecule target cellular compartments that are essential for DNA replication. Molbrick's platform technology was developed in Dr. Barak Akabayov's lab at Ben-Gurion University.
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is Molbrick's primary focus?
- Molbrick is an Israeli startup developing novel antimicrobial agents specifically designed to treat drug-resistant mycobacteria.
- When was Molbrick founded?
- Molbrick was founded in January 2019.
- Where is Molbrick's headquarters located?
- Molbrick's headquarters is located in Be'er Sheva, South District, Israel.
- What is the current employee count for Molbrick?
- Molbrick currently has 6 employees.
- What is Molbrick's current funding stage?
- Molbrick is currently in the Pre-Funding stage.
- What is the origin of Molbrick's platform technology?
- Molbrick's platform technology was developed in Dr. Barak Akabayov's lab at Ben-Gurion University.
- Who is a known founder of Molbrick?
- Barak Akabayov is a founder of Molbrick.
- What is Molbrick's primary sector?
- Molbrick's primary sector is Health Tech & Life Sciences.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMicroorganisms
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Highlights
Verified
Tags
pharmaceuticalsmicrobiology